 | • レポートコード：MRC2-11QY12897 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は子宮筋腫塞栓術のグローバル市場について調査・分析したレポートです。種類別（ゼラチンスポンジ、ポリビニルアルコール（PVA）粒子、トリアクリルゼラチンミクロスフェア（TAGM）、ポリメチルメタクリレート（PMMA）ミクロスフェア、その他）市場規模、用途別（臨床研究所、病院、外科センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別子宮筋腫塞栓術の競争状況、市場シェア ・世界の子宮筋腫塞栓術市場：種類別市場規模 2015年-2020年（ゼラチンスポンジ、ポリビニルアルコール（PVA）粒子、トリアクリルゼラチンミクロスフェア（TAGM）、ポリメチルメタクリレート（PMMA）ミクロスフェア、その他） ・世界の子宮筋腫塞栓術市場：種類別市場規模予測 2021年-2026年（ゼラチンスポンジ、ポリビニルアルコール（PVA）粒子、トリアクリルゼラチンミクロスフェア（TAGM）、ポリメチルメタクリレート（PMMA）ミクロスフェア、その他） ・世界の子宮筋腫塞栓術市場：用途別市場規模 2015年-2020年（臨床研究所、病院、外科センター、その他） ・世界の子宮筋腫塞栓術市場：用途別市場規模予測 2021年-2026年（臨床研究所、病院、外科センター、その他） ・北米の子宮筋腫塞栓術市場分析：米国、カナダ ・ヨーロッパの子宮筋腫塞栓術市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの子宮筋腫塞栓術市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の子宮筋腫塞栓術市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの子宮筋腫塞栓術市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Astellas Pharma、Nippon Kayaku、Pfizer、Boston Scientific Corporation、Merit Medical Systems、Cook Medical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Uterine fibroid embolization (UFE) is an effective, non-surgical method used to treat uterine fibroids in the fertile women population. It is performed with the help of uterine fibroid embolization agents, delivered to the tumor by micro-catheters. The embolization agents block the arteries supplying blood to the tumor and force them to shrink.
The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global market for uterine fibroid embolization agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market.
Market Analysis and Insights: Global Uterine Fibroid Embolization Agents Market
The global Uterine Fibroid Embolization Agents market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Uterine Fibroid Embolization Agents Scope and Market Size
Uterine Fibroid Embolization Agents market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Uterine Fibroid Embolization Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Uterine Fibroid Embolization Agents market is segmented into
Gelatin Sponge
Polyvinyl Alcohol (PVA) Particles
Trisacryl Gelatin Microspheres (TAGM)
Polymethyl Methacrylate (PMMA) Microspheres
Others
Segment by Application, the Uterine Fibroid Embolization Agents market is segmented into
Clinical Research Institutes
Hospital
Surgical Centers
Others
Regional and Country-level Analysis
The Uterine Fibroid Embolization Agents market is analysed and market size information is provided by regions (countries).
The key regions covered in the Uterine Fibroid Embolization Agents market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Uterine Fibroid Embolization Agents Market Share Analysis
Uterine Fibroid Embolization Agents market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Uterine Fibroid Embolization Agents business, the date to enter into the Uterine Fibroid Embolization Agents market, Uterine Fibroid Embolization Agents product introduction, recent developments, etc.
The major vendors covered:
Astellas Pharma
Nippon Kayaku
Pfizer
Boston Scientific Corporation
Merit Medical Systems
Cook Medical
…
1 Study Coverage
1.1 Uterine Fibroid Embolization Agents Product Introduction
1.2 Market Segments
1.3 Key Uterine Fibroid Embolization Agents Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Uterine Fibroid Embolization Agents Market Size Growth Rate by Type
1.4.2 Gelatin Sponge
1.4.3 Polyvinyl Alcohol (PVA) Particles
1.4.4 Trisacryl Gelatin Microspheres (TAGM)
1.4.5 Polymethyl Methacrylate (PMMA) Microspheres
1.4.6 Others
1.5 Market by Application
1.5.1 Global Uterine Fibroid Embolization Agents Market Size Growth Rate by Application
1.5.2 Clinical Research Institutes
1.5.3 Hospital
1.5.4 Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Uterine Fibroid Embolization Agents Market Size, Estimates and Forecasts
2.1.1 Global Uterine Fibroid Embolization Agents Revenue 2015-2026
2.1.2 Global Uterine Fibroid Embolization Agents Sales 2015-2026
2.2 Global Uterine Fibroid Embolization Agents, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Uterine Fibroid Embolization Agents Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Uterine Fibroid Embolization Agents Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Uterine Fibroid Embolization Agents Competitor Landscape by Players
3.1 Uterine Fibroid Embolization Agents Sales by Manufacturers
3.1.1 Uterine Fibroid Embolization Agents Sales by Manufacturers (2015-2020)
3.1.2 Uterine Fibroid Embolization Agents Sales Market Share by Manufacturers (2015-2020)
3.2 Uterine Fibroid Embolization Agents Revenue by Manufacturers
3.2.1 Uterine Fibroid Embolization Agents Revenue by Manufacturers (2015-2020)
3.2.2 Uterine Fibroid Embolization Agents Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Uterine Fibroid Embolization Agents Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Uterine Fibroid Embolization Agents Revenue in 2019
3.2.5 Global Uterine Fibroid Embolization Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Uterine Fibroid Embolization Agents Price by Manufacturers
3.4 Uterine Fibroid Embolization Agents Manufacturing Base Distribution, Product Types
3.4.1 Uterine Fibroid Embolization Agents Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Uterine Fibroid Embolization Agents Product Type
3.4.3 Date of International Manufacturers Enter into Uterine Fibroid Embolization Agents Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Uterine Fibroid Embolization Agents Market Size by Type (2015-2020)
4.1.1 Global Uterine Fibroid Embolization Agents Sales by Type (2015-2020)
4.1.2 Global Uterine Fibroid Embolization Agents Revenue by Type (2015-2020)
4.1.3 Uterine Fibroid Embolization Agents Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Uterine Fibroid Embolization Agents Market Size Forecast by Type (2021-2026)
4.2.1 Global Uterine Fibroid Embolization Agents Sales Forecast by Type (2021-2026)
4.2.2 Global Uterine Fibroid Embolization Agents Revenue Forecast by Type (2021-2026)
4.2.3 Uterine Fibroid Embolization Agents Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Uterine Fibroid Embolization Agents Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Uterine Fibroid Embolization Agents Market Size by Application (2015-2020)
5.1.1 Global Uterine Fibroid Embolization Agents Sales by Application (2015-2020)
5.1.2 Global Uterine Fibroid Embolization Agents Revenue by Application (2015-2020)
5.1.3 Uterine Fibroid Embolization Agents Price by Application (2015-2020)
5.2 Uterine Fibroid Embolization Agents Market Size Forecast by Application (2021-2026)
5.2.1 Global Uterine Fibroid Embolization Agents Sales Forecast by Application (2021-2026)
5.2.2 Global Uterine Fibroid Embolization Agents Revenue Forecast by Application (2021-2026)
5.2.3 Global Uterine Fibroid Embolization Agents Price Forecast by Application (2021-2026)
6 North America
6.1 North America Uterine Fibroid Embolization Agents by Country
6.1.1 North America Uterine Fibroid Embolization Agents Sales by Country
6.1.2 North America Uterine Fibroid Embolization Agents Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Uterine Fibroid Embolization Agents Market Facts & Figures by Type
6.3 North America Uterine Fibroid Embolization Agents Market Facts & Figures by Application
7 Europe
7.1 Europe Uterine Fibroid Embolization Agents by Country
7.1.1 Europe Uterine Fibroid Embolization Agents Sales by Country
7.1.2 Europe Uterine Fibroid Embolization Agents Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Uterine Fibroid Embolization Agents Market Facts & Figures by Type
7.3 Europe Uterine Fibroid Embolization Agents Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Uterine Fibroid Embolization Agents by Region
8.1.1 Asia Pacific Uterine Fibroid Embolization Agents Sales by Region
8.1.2 Asia Pacific Uterine Fibroid Embolization Agents Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Uterine Fibroid Embolization Agents Market Facts & Figures by Type
8.3 Asia Pacific Uterine Fibroid Embolization Agents Market Facts & Figures by Application
9 Latin America
9.1 Latin America Uterine Fibroid Embolization Agents by Country
9.1.1 Latin America Uterine Fibroid Embolization Agents Sales by Country
9.1.2 Latin America Uterine Fibroid Embolization Agents Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Uterine Fibroid Embolization Agents Market Facts & Figures by Type
9.3 Central & South America Uterine Fibroid Embolization Agents Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Uterine Fibroid Embolization Agents by Country
10.1.1 Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country
10.1.2 Middle East and Africa Uterine Fibroid Embolization Agents Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Uterine Fibroid Embolization Agents Market Facts & Figures by Type
10.3 Middle East and Africa Uterine Fibroid Embolization Agents Market Facts & Figures by Application
11 Company Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Corporation Information
11.1.2 Astellas Pharma Description and Business Overview
11.1.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma Uterine Fibroid Embolization Agents Products Offered
11.1.5 Astellas Pharma Related Developments
11.2 Nippon Kayaku
11.2.1 Nippon Kayaku Corporation Information
11.2.2 Nippon Kayaku Description and Business Overview
11.2.3 Nippon Kayaku Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Nippon Kayaku Uterine Fibroid Embolization Agents Products Offered
11.2.5 Nippon Kayaku Related Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description and Business Overview
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Uterine Fibroid Embolization Agents Products Offered
11.3.5 Pfizer Related Developments
11.4 Boston Scientific Corporation
11.4.1 Boston Scientific Corporation Corporation Information
11.4.2 Boston Scientific Corporation Description and Business Overview
11.4.3 Boston Scientific Corporation Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Boston Scientific Corporation Uterine Fibroid Embolization Agents Products Offered
11.4.5 Boston Scientific Corporation Related Developments
11.5 Merit Medical Systems
11.5.1 Merit Medical Systems Corporation Information
11.5.2 Merit Medical Systems Description and Business Overview
11.5.3 Merit Medical Systems Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merit Medical Systems Uterine Fibroid Embolization Agents Products Offered
11.5.5 Merit Medical Systems Related Developments
11.6 Cook Medical
11.6.1 Cook Medical Corporation Information
11.6.2 Cook Medical Description and Business Overview
11.6.3 Cook Medical Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Cook Medical Uterine Fibroid Embolization Agents Products Offered
11.6.5 Cook Medical Related Developments
11.1 Astellas Pharma
11.1.1 Astellas Pharma Corporation Information
11.1.2 Astellas Pharma Description and Business Overview
11.1.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma Uterine Fibroid Embolization Agents Products Offered
11.1.5 Astellas Pharma Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Uterine Fibroid Embolization Agents Market Estimates and Projections by Region
12.1.1 Global Uterine Fibroid Embolization Agents Sales Forecast by Regions 2021-2026
12.1.2 Global Uterine Fibroid Embolization Agents Revenue Forecast by Regions 2021-2026
12.2 North America Uterine Fibroid Embolization Agents Market Size Forecast (2021-2026)
12.2.1 North America: Uterine Fibroid Embolization Agents Sales Forecast (2021-2026)
12.2.2 North America: Uterine Fibroid Embolization Agents Revenue Forecast (2021-2026)
12.2.3 North America: Uterine Fibroid Embolization Agents Market Size Forecast by Country (2021-2026)
12.3 Europe Uterine Fibroid Embolization Agents Market Size Forecast (2021-2026)
12.3.1 Europe: Uterine Fibroid Embolization Agents Sales Forecast (2021-2026)
12.3.2 Europe: Uterine Fibroid Embolization Agents Revenue Forecast (2021-2026)
12.3.3 Europe: Uterine Fibroid Embolization Agents Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Uterine Fibroid Embolization Agents Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Uterine Fibroid Embolization Agents Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Uterine Fibroid Embolization Agents Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Uterine Fibroid Embolization Agents Market Size Forecast by Region (2021-2026)
12.5 Latin America Uterine Fibroid Embolization Agents Market Size Forecast (2021-2026)
12.5.1 Latin America: Uterine Fibroid Embolization Agents Sales Forecast (2021-2026)
12.5.2 Latin America: Uterine Fibroid Embolization Agents Revenue Forecast (2021-2026)
12.5.3 Latin America: Uterine Fibroid Embolization Agents Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Uterine Fibroid Embolization Agents Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Uterine Fibroid Embolization Agents Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Uterine Fibroid Embolization Agents Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Uterine Fibroid Embolization Agents Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Uterine Fibroid Embolization Agents Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Uterine Fibroid Embolization Agents Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Uterine Fibroid Embolization Agents Market Segments
Table 2. Ranking of Global Top Uterine Fibroid Embolization Agents Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Uterine Fibroid Embolization Agents Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Gelatin Sponge
Table 5. Major Manufacturers of Polyvinyl Alcohol (PVA) Particles
Table 6. Major Manufacturers of Trisacryl Gelatin Microspheres (TAGM)
Table 7. Major Manufacturers of Polymethyl Methacrylate (PMMA) Microspheres
Table 8. Major Manufacturers of Others
Table 9. Global Uterine Fibroid Embolization Agents Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global Uterine Fibroid Embolization Agents Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global Uterine Fibroid Embolization Agents Sales by Regions 2015-2020 (K Units)
Table 12. Global Uterine Fibroid Embolization Agents Sales Market Share by Regions (2015-2020)
Table 13. Global Uterine Fibroid Embolization Agents Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Uterine Fibroid Embolization Agents Sales by Manufacturers (2015-2020) (K Units)
Table 15. Global Uterine Fibroid Embolization Agents Sales Share by Manufacturers (2015-2020)
Table 16. Global Uterine Fibroid Embolization Agents Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Uterine Fibroid Embolization Agents by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Fibroid Embolization Agents as of 2019)
Table 18. Uterine Fibroid Embolization Agents Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Uterine Fibroid Embolization Agents Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Uterine Fibroid Embolization Agents Price (2015-2020) (USD/Unit)
Table 21. Uterine Fibroid Embolization Agents Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Uterine Fibroid Embolization Agents Product Type
Table 23. Date of International Manufacturers Enter into Uterine Fibroid Embolization Agents Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Uterine Fibroid Embolization Agents Sales by Type (2015-2020) (K Units)
Table 26. Global Uterine Fibroid Embolization Agents Sales Share by Type (2015-2020)
Table 27. Global Uterine Fibroid Embolization Agents Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Uterine Fibroid Embolization Agents Revenue Share by Type (2015-2020)
Table 29. Uterine Fibroid Embolization Agents Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 30. Global Uterine Fibroid Embolization Agents Sales by Application (2015-2020) (K Units)
Table 31. Global Uterine Fibroid Embolization Agents Sales Share by Application (2015-2020)
Table 32. North America Uterine Fibroid Embolization Agents Sales by Country (2015-2020) (K Units)
Table 33. North America Uterine Fibroid Embolization Agents Sales Market Share by Country (2015-2020)
Table 34. North America Uterine Fibroid Embolization Agents Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Uterine Fibroid Embolization Agents Revenue Market Share by Country (2015-2020)
Table 36. North America Uterine Fibroid Embolization Agents Sales by Type (2015-2020) (K Units)
Table 37. North America Uterine Fibroid Embolization Agents Sales Market Share by Type (2015-2020)
Table 38. North America Uterine Fibroid Embolization Agents Sales by Application (2015-2020) (K Units)
Table 39. North America Uterine Fibroid Embolization Agents Sales Market Share by Application (2015-2020)
Table 40. Europe Uterine Fibroid Embolization Agents Sales by Country (2015-2020) (K Units)
Table 41. Europe Uterine Fibroid Embolization Agents Sales Market Share by Country (2015-2020)
Table 42. Europe Uterine Fibroid Embolization Agents Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Uterine Fibroid Embolization Agents Revenue Market Share by Country (2015-2020)
Table 44. Europe Uterine Fibroid Embolization Agents Sales by Type (2015-2020) (K Units)
Table 45. Europe Uterine Fibroid Embolization Agents Sales Market Share by Type (2015-2020)
Table 46. Europe Uterine Fibroid Embolization Agents Sales by Application (2015-2020) (K Units)
Table 47. Europe Uterine Fibroid Embolization Agents Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Uterine Fibroid Embolization Agents Sales by Region (2015-2020) (K Units)
Table 49. Asia Pacific Uterine Fibroid Embolization Agents Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Uterine Fibroid Embolization Agents Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Uterine Fibroid Embolization Agents Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Uterine Fibroid Embolization Agents Sales by Type (2015-2020) (K Units)
Table 53. Asia Pacific Uterine Fibroid Embolization Agents Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Uterine Fibroid Embolization Agents Sales by Application (2015-2020) (K Units)
Table 55. Asia Pacific Uterine Fibroid Embolization Agents Sales Market Share by Application (2015-2020)
Table 56. Latin America Uterine Fibroid Embolization Agents Sales by Country (2015-2020) (K Units)
Table 57. Latin America Uterine Fibroid Embolization Agents Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Uterine Fibroid Embolization Agents Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Uterine Fibroid Embolization Agents Revenue Market Share by Country (2015-2020)
Table 60. Latin America Uterine Fibroid Embolization Agents Sales by Type (2015-2020) (K Units)
Table 61. Latin America Uterine Fibroid Embolization Agents Sales Market Share by Type (2015-2020)
Table 62. Latin America Uterine Fibroid Embolization Agents Sales by Application (2015-2020) (K Units)
Table 63. Latin America Uterine Fibroid Embolization Agents Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country (2015-2020) (K Units)
Table 65. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Uterine Fibroid Embolization Agents Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Uterine Fibroid Embolization Agents Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Type (2015-2020) (K Units)
Table 69. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Application (2015-2020) (K Units)
Table 71. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share by Application (2015-2020)
Table 72. Astellas Pharma Corporation Information
Table 73. Astellas Pharma Description and Major Businesses
Table 74. Astellas Pharma Uterine Fibroid Embolization Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 75. Astellas Pharma Product
Table 76. Astellas Pharma Recent Development
Table 77. Nippon Kayaku Corporation Information
Table 78. Nippon Kayaku Description and Major Businesses
Table 79. Nippon Kayaku Uterine Fibroid Embolization Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Nippon Kayaku Product
Table 81. Nippon Kayaku Recent Development
Table 82. Pfizer Corporation Information
Table 83. Pfizer Description and Major Businesses
Table 84. Pfizer Uterine Fibroid Embolization Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Pfizer Product
Table 86. Pfizer Recent Development
Table 87. Boston Scientific Corporation Corporation Information
Table 88. Boston Scientific Corporation Description and Major Businesses
Table 89. Boston Scientific Corporation Uterine Fibroid Embolization Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Boston Scientific Corporation Product
Table 91. Boston Scientific Corporation Recent Development
Table 92. Merit Medical Systems Corporation Information
Table 93. Merit Medical Systems Description and Major Businesses
Table 94. Merit Medical Systems Uterine Fibroid Embolization Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Merit Medical Systems Product
Table 96. Merit Medical Systems Recent Development
Table 97. Cook Medical Corporation Information
Table 98. Cook Medical Description and Major Businesses
Table 99. Cook Medical Uterine Fibroid Embolization Agents Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Cook Medical Product
Table 101. Cook Medical Recent Development
Table 102. Global Uterine Fibroid Embolization Agents Sales Forecast by Regions (2021-2026) (K Units)
Table 103. Global Uterine Fibroid Embolization Agents Sales Market Share Forecast by Regions (2021-2026)
Table 104. Global Uterine Fibroid Embolization Agents Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 105. Global Uterine Fibroid Embolization Agents Revenue Market Share Forecast by Regions (2021-2026)
Table 106. North America: Uterine Fibroid Embolization Agents Sales Forecast by Country (2021-2026) (K Units)
Table 107. North America: Uterine Fibroid Embolization Agents Revenue Forecast by Country (2021-2026) (US$ Million)
Table 108. Europe: Uterine Fibroid Embolization Agents Sales Forecast by Country (2021-2026) (K Units)
Table 109. Europe: Uterine Fibroid Embolization Agents Revenue Forecast by Country (2021-2026) (US$ Million)
Table 110. Asia Pacific: Uterine Fibroid Embolization Agents Sales Forecast by Region (2021-2026) (K Units)
Table 111. Asia Pacific: Uterine Fibroid Embolization Agents Revenue Forecast by Region (2021-2026) (US$ Million)
Table 112. Latin America: Uterine Fibroid Embolization Agents Sales Forecast by Country (2021-2026) (K Units)
Table 113. Latin America: Uterine Fibroid Embolization Agents Revenue Forecast by Country (2021-2026) (US$ Million)
Table 114. Middle East and Africa: Uterine Fibroid Embolization Agents Sales Forecast by Country (2021-2026) (K Units)
Table 115. Middle East and Africa: Uterine Fibroid Embolization Agents Revenue Forecast by Country (2021-2026) (US$ Million)
Table 116. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 117. Key Challenges
Table 118. Market Risks
Table 119. Main Points Interviewed from Key Uterine Fibroid Embolization Agents Players
Table 120. Uterine Fibroid Embolization Agents Customers List
Table 121. Uterine Fibroid Embolization Agents Distributors List
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Uterine Fibroid Embolization Agents Product Picture
Figure 2. Global Uterine Fibroid Embolization Agents Sales Market Share by Type in 2020 & 2026
Figure 3. Gelatin Sponge Product Picture
Figure 4. Polyvinyl Alcohol (PVA) Particles Product Picture
Figure 5. Trisacryl Gelatin Microspheres (TAGM) Product Picture
Figure 6. Polymethyl Methacrylate (PMMA) Microspheres Product Picture
Figure 7. Others Product Picture
Figure 8. Global Uterine Fibroid Embolization Agents Sales Market Share by Application in 2020 & 2026
Figure 9. Clinical Research Institutes
Figure 10. Hospital
Figure 11. Surgical Centers
Figure 12. Others
Figure 13. Uterine Fibroid Embolization Agents Report Years Considered
Figure 14. Global Uterine Fibroid Embolization Agents Market Size 2015-2026 (US$ Million)
Figure 15. Global Uterine Fibroid Embolization Agents Sales 2015-2026 (K Units)
Figure 16. Global Uterine Fibroid Embolization Agents Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Uterine Fibroid Embolization Agents Sales Market Share by Region (2015-2020)
Figure 18. Global Uterine Fibroid Embolization Agents Sales Market Share by Region in 2019
Figure 19. Global Uterine Fibroid Embolization Agents Revenue Market Share by Region (2015-2020)
Figure 20. Global Uterine Fibroid Embolization Agents Revenue Market Share by Region in 2019
Figure 21. Global Uterine Fibroid Embolization Agents Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Uterine Fibroid Embolization Agents Revenue in 2019
Figure 23. Uterine Fibroid Embolization Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Uterine Fibroid Embolization Agents Sales Market Share by Type (2015-2020)
Figure 25. Global Uterine Fibroid Embolization Agents Sales Market Share by Type in 2019
Figure 26. Global Uterine Fibroid Embolization Agents Revenue Market Share by Type (2015-2020)
Figure 27. Global Uterine Fibroid Embolization Agents Revenue Market Share by Type in 2019
Figure 28. Global Uterine Fibroid Embolization Agents Market Share by Price Range (2015-2020)
Figure 29. Global Uterine Fibroid Embolization Agents Sales Market Share by Application (2015-2020)
Figure 30. Global Uterine Fibroid Embolization Agents Sales Market Share by Application in 2019
Figure 31. Global Uterine Fibroid Embolization Agents Revenue Market Share by Application (2015-2020)
Figure 32. Global Uterine Fibroid Embolization Agents Revenue Market Share by Application in 2019
Figure 33. North America Uterine Fibroid Embolization Agents Sales Growth Rate 2015-2020 (K Units)
Figure 34. North America Uterine Fibroid Embolization Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Uterine Fibroid Embolization Agents Sales Market Share by Country in 2019
Figure 36. North America Uterine Fibroid Embolization Agents Revenue Market Share by Country in 2019
Figure 37. U.S. Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 38. U.S. Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 40. Canada Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Uterine Fibroid Embolization Agents Market Share by Type in 2019
Figure 42. North America Uterine Fibroid Embolization Agents Market Share by Application in 2019
Figure 43. Europe Uterine Fibroid Embolization Agents Sales Growth Rate 2015-2020 (K Units)
Figure 44. Europe Uterine Fibroid Embolization Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Uterine Fibroid Embolization Agents Sales Market Share by Country in 2019
Figure 46. Europe Uterine Fibroid Embolization Agents Revenue Market Share by Country in 2019
Figure 47. Germany Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 48. Germany Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 50. France Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 52. U.K. Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 54. Italy Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 56. Russia Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Uterine Fibroid Embolization Agents Market Share by Type in 2019
Figure 58. Europe Uterine Fibroid Embolization Agents Market Share by Application in 2019
Figure 59. Asia Pacific Uterine Fibroid Embolization Agents Sales Growth Rate 2015-2020 (K Units)
Figure 60. Asia Pacific Uterine Fibroid Embolization Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Uterine Fibroid Embolization Agents Sales Market Share by Region in 2019
Figure 62. Asia Pacific Uterine Fibroid Embolization Agents Revenue Market Share by Region in 2019
Figure 63. China Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 64. China Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 66. Japan Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 68. South Korea Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 70. India Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 72. Australia Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 74. Taiwan Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 76. Indonesia Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 78. Thailand Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 80. Malaysia Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 82. Philippines Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 84. Vietnam Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Uterine Fibroid Embolization Agents Market Share by Type in 2019
Figure 86. Asia Pacific Uterine Fibroid Embolization Agents Market Share by Application in 2019
Figure 87. Latin America Uterine Fibroid Embolization Agents Sales Growth Rate 2015-2020 (K Units)
Figure 88. Latin America Uterine Fibroid Embolization Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Uterine Fibroid Embolization Agents Sales Market Share by Country in 2019
Figure 90. Latin America Uterine Fibroid Embolization Agents Revenue Market Share by Country in 2019
Figure 91. Mexico Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 92. Mexico Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 94. Brazil Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 96. Argentina Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Uterine Fibroid Embolization Agents Market Share by Type in 2019
Figure 98. Latin America Uterine Fibroid Embolization Agents Market Share by Application in 2019
Figure 99. Middle East and Africa Uterine Fibroid Embolization Agents Sales Growth Rate 2015-2020 (K Units)
Figure 100. Middle East and Africa Uterine Fibroid Embolization Agents Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Uterine Fibroid Embolization Agents Revenue Market Share by Country in 2019
Figure 103. Turkey Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 104. Turkey Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 106. Saudi Arabia Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Uterine Fibroid Embolization Agents Sales Growth Rate (2015-2020) (K Units)
Figure 108. U.A.E Uterine Fibroid Embolization Agents Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Uterine Fibroid Embolization Agents Market Share by Type in 2019
Figure 110. Middle East and Africa Uterine Fibroid Embolization Agents Market Share by Application in 2019
Figure 111. North America Uterine Fibroid Embolization Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. North America Uterine Fibroid Embolization Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Uterine Fibroid Embolization Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Europe Uterine Fibroid Embolization Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Uterine Fibroid Embolization Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Asia Pacific Uterine Fibroid Embolization Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Uterine Fibroid Embolization Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Latin America Uterine Fibroid Embolization Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Uterine Fibroid Embolization Agents Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 120. Middle East and Africa Uterine Fibroid Embolization Agents Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
子宮筋腫治療装置の世界市場（～2026年） Uterine fibroids are noncancerous growths of the uterus that often appear during childbearing years. Also called leiomyomas (lie-o-my-O-muhs) or myomas, uterine fibroids aren't associated with an increased risk of uterine cancer and almost never develop into cancer. Market Analysis and Insights: Glo…- トリスアクリルゼラチンミクロスフェアの世界市場（～2026年） Market Analysis and Insights: Global Tris-acryl Gelatin Microspheres Market The global Tris-acryl Gelatin Microspheres market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Tris-acryl Gelatin Microspheres Scope and Market Si…
- PVAフォーム塞栓粒子の世界市場（～2026年） Market Analysis and Insights: Global PVA Foam Embolization Particles Market The global PVA Foam Embolization Particles market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global PVA Foam Embolization Particles Scope and Market Si…
- 子宮がん診断検査の世界市場（～2026年） Uterus a female organ also referred as the womb is located in the lower abdomen. It supports in the fetal development until birth. In North America, the U.S. is expected to be the dominant market for uterine cancer diagnostic testing due to growing incidence of uterine cancer. Market Analysis and In…
- 子宮内膜ポリープ治療薬の世界市場（～2026年） Uterine polyps are common gynecological diseases. Broadly speaking, it refers to all tumors attached to the uterine wall by slender pedicle. Mostly benign. Market Analysis and Insights: Global Uterine Polyps Drug Market The global Uterine Polyps Drug market size is projected to reach US$ XX million …